| Big Pharma's Emerging Market Fever: Abbott Aims for the Top of India's Industry The Burrill Report submits: By Marie Daghlian Emerging market M&A headlined the third week of May as Big Pharma continued its push into emerging markets. Abbott Laboratories (ABT) wasted no time after creating its Established Product Division to expand its branded generics market share, especially in emerging markets. The company announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business, one of India’s top branded generics companies, for an upfront payment of $2.1 billion, plus $400 million annually for the next four years. The $3.7 billion deal will make Abbott in the leader in the Indian pharmaceutical market. Complete Story » seekingalpha.com |
FDA Extends Gardasil Review FDA has extended its review of Merck's application to broaden the use of its cervical-cancer vaccine, Gardasil, to include older women. online.wsj.com |
Vertex: At the Finish Line for a Hepatitis C Cure Prohost Biotech submits:When an investigational drug proves it can eradicate a virus we call it a breakthrough. The nearest to approval of the expected breakthroughs is Vertex’s (VRTX) drug telaprevir, a specific hepatitis C virus protease inhibitor. The drug was a blessing for the infected victims who had it in clinical trials. It brought a miracle happy ending to what seemed to be an endless nightmare of acute liver inflammation, chronic liver inflammation, liver cirrhosis, liver transplant and possible liver cancer. We expected telaprevir to be greeted positively by the government and insurance companies, which spend tons of money on the HCV liver problems where treatments that do not work are, nevertheless, paid for.More than anybody else, we expected they would cheer the news about the successful outcome of telaprevir in clearing the virus in large clinical trials. We were confident that they will not overlook Vertex's drug importance, its huge market and the fact that it is expected to be the first approved protease inhibitor, i.e., the first approved drug to that deals with the virus itself, not only its symptoms. We thought they would rush to buy VRTX as undervalued as it is and as it has constantly been for the past three years. Surprisingly enough, investors seemed uninterested in the $10 B market and, instead of buying the stock, they kept trading up and down, but to the negative side. The reason, as we see it, is that investors believe that the real influence on stock pricing comes not from the firms’ good news, or expected huge revenues and sales growth, but from emperors who dictate the prices of the publicly-traded firms. Complete Story » seekingalpha.com |
Cadus: Buying a Dollar for 50 Cents, Literally Stirling Capital Management submits: KDUS: Cadus Corporation Current Price: $1.43 Price Target: $1.80 - $2.40Complete Story » seekingalpha.com |
PAREXEL International to Present at Oppenheimer Healthcare Conference and Morningstar Annual Stocks Forum [PR Newswire] - PAREXEL International Corporation announced today it will be presenting at the Oppenheimer Healthcare Conference in New York. Â James Winschel, Senior Vice President and Chief Financial Officer will be making a presentation on PAREXEL at 2:45 p.m. E.T. on Wednesday, November 3, 2010. us.rd.yahoo.com |